profit from every $100 of sales.
$0$100
HeartBeam
$0.40-1.78% today
-75.8% in 1 year
1-year low $0.361-year high $3.44
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What HeartBeam sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$21.0 million of profit last year.
SalesProfit
HeartBeam vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| HeartBeam | No profit yet | ||
 GE HealthCare Technologies | 17.8× · Fair price | ||
 BrightSpring Health Services | 74.6× · Very expensive | ||
 Tempus AI | No profit yet | ||
 HealthEquity | 39.6× · Expensive |
AI analysis
An AI analyst reads HeartBeam's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -13 | -15 | -20 | -21 | |
| -13 | -15 | -20 | -21 | |
| -13 | -15 | -19 | -21 | |
| -1.59 | -0.72 | -0.73 | -0.62 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 4 | 17 | 3 | 6 |
| Cash | 4 | 16 | 2 | 4 |
| Total debt | – | – | – | – |
| Total liabilities | 2 | 1 | 2 | 3 |
| 2 | 16 | 2 | 3 | |
| 8 | 20 | 27 | 34 | |
| -433.6% | -75.9% | -949.9% | -641.6% | |
| -546.0% | -91.9% | -1,175.8% | -807.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -10 | -12 | -14 | -14 | |
| – | 0 | 0 | 1 | |
| -10 | -12 | -15 | -15 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 3 | 4 | 5 |
Valuation
- –
- –
- –
- 11.5×
- –
- –
- –
- -64.1%
- -92.4%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -812.1%
- -530.8%
- -571.1%
- -359.7%
- -812.1%
- –
Growth
- –
- –
- +0.6%
- –
- +44.1%
Financial health
- -0.2×
- 0.00
- 0.0%
- –
- 1.45
- 1.41
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 883
Bottom 1%of 985
What analysts expect
- Average price target
- $5.50
- Range
- $5.50 – $5.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.12 | -0.14 | +14.3% |
| Mar 12, 2026 | -0.14 | -0.13 | −7.7% |
| Nov 13, 2025 | -0.15 | -0.16 | +6.3% |
| Aug 13, 2025 | -0.15 | -0.16 | +6.3% |
| May 13, 2025 | -0.18 | -0.15 | −20.0% |
| Mar 13, 2025 | -0.18 | -0.19 | +5.3% |
| Nov 7, 2024 | -0.19 | -0.17 | −11.8% |
| Aug 14, 2024 | -0.19 | -0.16 | −18.8% |
News
Cerebras shares jump 16% as earnings beat and Microsoft deal fuel raised outlookYahoo Finance · Nov 13, 2026MP Gains 2% After Q3 Earnings Beat: Reason Enough to Buy the Stock?Yahoo Finance · Nov 12, 2026Stock Market Today, Nov. 9: Grab Holdings Jumps on Record Adjusted EBITDA and Q3 Revenue BeatYahoo Finance · Nov 9, 2026Earnings Scoreboard: 86% of reporting firms beat EPS estimates, 78% post Y/Y earnings growthSeeking Alpha · Nov 7, 2026After the Midterm Rally, the Dow Is on Track to Beat the Nasdaq for the First Time Since 2022. Here's What History Says Could Come Next.Yahoo Finance · Nov 6, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
17No pass
Benjamin Graham
28No pass
Philip Fisher
31No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
38No pass
Terry Smith
34No pass
Questions about HeartBeam
Is HeartBeam a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the HeartBeam AI analysis
What does HeartBeam do?
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. It is in Medical - Healthcare Information Services.
Does HeartBeam pay a dividend?
No. HeartBeam does not pay a dividend at the moment.
Is HeartBeam stock halal?
Yes. HeartBeam passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has HeartBeam stock done over the past year?
Down 75.8% over the past twelve months, to $0.40. It traded between $0.36 and $3.44 and is 88.3% below its high.
Who are HeartBeam's competitors?
The largest listed companies in the same industry are GE HealthCare Technologies, BrightSpring Health Services, Tempus AI and HealthEquity. The peers table on this page compares their profit, growth and price with HeartBeam's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.